PopVax is Awarded 2 Million USD as One of the Winners of the BARDA Patch Forward Prize for its Seasonal Influenza Vaccine built on a Novel mRNA-encoded Immunogen Display Architecture Delivered via Dissolvable Microarray Patch
Reading Time: 3 minutes PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design, is delighted to announce that it has been awarded $2 million by the United States Biomedical Advanced Research and Development Authority (BARDA) as one of the winners of the Concept
Proposal of HKFoods Plc’s Shareholders’ Nomination Board to the following Annual General Meeting
Reading Time: 3 minutes HKFoods Plc, Stock Exchange Release 13 January 2025, at 5.45 pm EET The Shareholders’ Nomination Board of HKFoods Plc has prepared proposals on the composition and the remuneration of the Board of Directors to the HKFoods’ 2025 Annual General Meeting. Number
Arctic Bioscience – funded to cash positive
Reading Time: 2 minutes Arctic Bioscience is now funded through a NOK 30 million loan facility. Strong 30% y/y growth in sales revenues in 2024 and prospects of continued strong growth in coming years. Psoriasis drug candidate HRO350 on track for 12 months readout end of
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 13.01.2025
Reading Time: < 1 minute Stock Exchange Release 13.01.2025 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 13.01.2025 Date 13.01.2025 Exchange transaction Buy Share class FSKRS Amount 2000 Average price/share 14.5861 EUR Highest price/share 14.6200 EUR Lowest price/share
ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 13.01.2025
Reading Time: < 1 minute ALEXANDRIA GROUP OYJ NOTIFICATION 13.01.2025 at 18:30 EET ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 13.01.2025 Date 13.01.2025 Exchange transaction Buy Share class ALEX Amount 200 Average price/share 8,8500 EUR Highest
OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe
Reading Time: 3 minutes STOCKHOLM, SWEDEN – January 13, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces that the Company has entered into a non-binding agreement with the intention to partner with pharmaceutical leader Molteni Farmaceutici (“Molteni”) regarding exclusive rights to commercialization of BupiZenge™
Arctic Bioscience – Primary insiders participating in convertible loan facility
Reading Time: 2 minutes Reference is made to the stock exchange release from earlier today, 13th January 2025, regarding new funding, including a convertible loan facility of NOK 15 million. The following primary insiders, or closely related companies to primary insiders, are a part of
Nordea Bank Abp: Repurchase of own shares on 13.01.2025
Reading Time: < 1 minute Nordea Bank AbpStock exchange release – Changes in company’s own shares13.01.2025 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 13.01.2025 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading venue (MIC Code) Number of shares Weighted average
Financial effects as a result of the transfer of a majority stake in the subsidiary Rediem Capital AB
Reading Time: 2 minutes On 19 December 2024, TF Bank AB (publ) (“TF Bank” or the “Bank”) announced that the closing date for the transfer of the majority stake in the subsidiary Rediem Capital AB (“Rediem”) to Alektum Holding AB (publ) and Erik Selin Fastigheter
SciBase announces outcome of directed issue and preliminary outcome of rights issue
Reading Time: 7 minutes SciBase Holding AB (”SciBase” or the ”Company”) today announces the preliminary outcome of the capital raise, consisting of a rights issue of units of approximately SEK 59.3 million (the “Rights Issue”) and a directed issue of units, deviating from existing shareholders’ preferential